Tali Feferman

1.4k total citations
34 papers, 1.0k citations indexed

About

Tali Feferman is a scholar working on Neurology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Tali Feferman has authored 34 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Neurology, 15 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Immunology. Recurrent topics in Tali Feferman's work include Myasthenia Gravis and Thymoma (18 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and T-cell and B-cell Immunology (10 papers). Tali Feferman is often cited by papers focused on Myasthenia Gravis and Thymoma (18 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and T-cell and B-cell Immunology (10 papers). Tali Feferman collaborates with scholars based in Israel, France and United States. Tali Feferman's co-authors include Sara Fuchs, Miriam C. Souroujon, Revital Aricha, Guy Shakhar, Prasanta Kumar Maiti, Sonia Berrih‐Aknin, Avner Yayon, R Adar, Orit Segev and Efrat Monsonego‐Ornan and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Molecular and Cellular Biology.

In The Last Decade

Tali Feferman

34 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tali Feferman Israel 18 387 310 301 210 127 34 1.0k
Jian Rong Sheng United States 17 361 0.9× 284 0.9× 138 0.5× 106 0.5× 105 0.8× 30 820
Mahdia Benkhoucha Switzerland 18 657 1.7× 91 0.3× 266 0.9× 191 0.9× 41 0.3× 32 1.2k
Kevin R. Leiby United States 9 218 0.6× 83 0.3× 526 1.7× 98 0.5× 29 0.2× 10 855
Klaus‐Dieter Preuss Germany 20 414 1.1× 137 0.4× 401 1.3× 161 0.8× 23 0.2× 50 954
Jodi L. Karnell United States 17 789 2.0× 47 0.2× 279 0.9× 239 1.1× 44 0.3× 22 1.4k
Robert Medaer Belgium 15 1.1k 2.8× 97 0.3× 167 0.6× 163 0.8× 30 0.2× 24 1.4k
Ali Chahlavi United States 14 134 0.3× 177 0.6× 253 0.8× 257 1.2× 10 0.1× 21 872
Tone Berge Norway 17 268 0.7× 61 0.2× 474 1.6× 137 0.7× 29 0.2× 34 832
Judy Cossins United Kingdom 11 93 0.2× 584 1.9× 424 1.4× 198 0.9× 158 1.2× 12 1.4k
Yonghao Cao United States 14 524 1.4× 98 0.3× 243 0.8× 166 0.8× 48 0.4× 19 886

Countries citing papers authored by Tali Feferman

Since Specialization
Citations

This map shows the geographic impact of Tali Feferman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tali Feferman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tali Feferman more than expected).

Fields of papers citing papers by Tali Feferman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tali Feferman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tali Feferman. The network helps show where Tali Feferman may publish in the future.

Co-authorship network of co-authors of Tali Feferman

This figure shows the co-authorship network connecting the top 25 collaborators of Tali Feferman. A scholar is included among the top collaborators of Tali Feferman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tali Feferman. Tali Feferman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yalin, Adam, Tomer Landsberger, Ran Salomon, et al.. (2023). Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy. Science Immunology. 8(81). eadd8005–eadd8005. 28 indexed citations
2.
Salomon, Ran, Yonatan Katzenelenbogen, Assaf Weiner, et al.. (2022). Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nature Cancer. 3(3). 287–302. 53 indexed citations
3.
Feferman, Tali, David Morgenstern, Yaniv Lustig, et al.. (2021). Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. Cell Reports. 37(11). 110114–110114. 33 indexed citations
4.
Aharoni, Rina, Raya Eilam, Nofar Schottlender, et al.. (2020). Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis. Journal of Neuroimmunology. 345. 577281–577281. 12 indexed citations
5.
Shipony, Zohar, Masha Kolesnikov, Camila Avivi, et al.. (2019). Reduced CTL motility and activity in avascular tumor areas. Cancer Immunology Immunotherapy. 68(8). 1287–1301. 25 indexed citations
6.
Feferman, Tali, et al.. (2017). Culturing CTLs under Hypoxic Conditions Enhances Their Cytolysis and Improves Their Anti-tumor Function. Cell Reports. 20(11). 2547–2555. 135 indexed citations
7.
Maurer, Marie, Tali Feferman, Jacky Bismuth, et al.. (2015). IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis. Acta Neuropathologica Communications. 3(1). 1–1. 78 indexed citations
8.
Aricha, Revital, Tali Feferman, Tamar Paperna, et al.. (2010). Involvement of phosphodiesterases in autoimmune diseases. Journal of Neuroimmunology. 220(1-2). 43–51. 10 indexed citations
9.
Aricha, Revital, Tali Feferman, Hamish S. Scott, et al.. (2010). The susceptibility of Aire−/− mice to experimental myasthenia gravis involves alterations in regulatory T cells. Journal of Autoimmunity. 36(1). 16–24. 36 indexed citations
10.
Feferman, Tali, Revital Aricha, Erez Geron, et al.. (2009). Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-γ inducible protein 10 (IP-10) and its receptor CXCR3. Journal of Neuroimmunology. 209(1-2). 87–95. 18 indexed citations
11.
Fuchs, Sara, Tali Feferman, Raanan Margalit, et al.. (2008). A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. Journal of Neuroimmunology. 194(1-2). 89–96. 22 indexed citations
12.
Fuchs, Sara, Tali Feferman, Raanan Margalit, et al.. (2008). Immunosuppression of EAMG by IVIG Is Mediated by a Disease‐specific Anti‐immunoglobulin Fraction. Annals of the New York Academy of Sciences. 1132(1). 244–248. 10 indexed citations
13.
Feferman, Tali, et al.. (2008). Suppression of experimental autoimmune myasthenia gravis by combination therapy: Pentoxifylline as a steroid-sparing agent. Journal of Neuroimmunology. 201-202. 128–135. 7 indexed citations
14.
Fuchs, Sara, et al.. (2007). Suppression of Experimental Autoimmune Myasthenia Gravis by Intravenous Immunoglobulin and Isolation of a Disease‐Specific IgG Fraction. Annals of the New York Academy of Sciences. 1110(1). 550–558. 8 indexed citations
15.
Feferman, Tali, et al.. (2006). Intravenous immunoglobulin suppresses experimental myasthenia gravis: Immunological mechanisms. Journal of Neuroimmunology. 176(1-2). 187–197. 28 indexed citations
16.
Feferman, Tali, Prasanta Kumar Maiti, Sonia Berrih‐Aknin, et al.. (2005). Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis. The Journal of Immunology. 174(9). 5324–5331. 76 indexed citations
17.
Maiti, Prasanta Kumar, Tali Feferman, Sin‐Hyeog Im, Miriam C. Souroujon, & Sara Fuchs. (2004). Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. Journal of Neuroimmunology. 152(1-2). 112–120. 39 indexed citations
18.
Souroujon, Miriam C., Prasanta Kumar Maiti, Tali Feferman, et al.. (2003). Suppression of Myasthenia Gravis by Antigen‐Specific Mucosal Tolerance and Modulation of Cytokines and Costimulatory Factors. Annals of the New York Academy of Sciences. 998(1). 533–536. 16 indexed citations
19.
Im, Sin‐Hyeog, Dora Barchan, Tali Feferman, et al.. (2002). Protective molecular mimicry in experimental myasthenia gravis. Journal of Neuroimmunology. 126(1-2). 99–106. 10 indexed citations
20.
Cooper, Desmond W., Elizabeth A. Holland, Jennifer A. Donald, et al.. (1994). Phosphoglycerate kinase pseudogenes in the tammar wallaby and other macropodid marsupials. Mammalian Genome. 5(9). 531–537. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jian Rong Sheng Breakdown of academic impact, for papers by Mahdia Benkhoucha Breakdown of academic impact, for papers by Kevin R. Leiby Breakdown of academic impact, for papers by Klaus‐Dieter Preuss Breakdown of academic impact, for papers by Jodi L. Karnell Breakdown of academic impact, for papers by Robert Medaer Breakdown of academic impact, for papers by Ali Chahlavi Breakdown of academic impact, for papers by Tone Berge Breakdown of academic impact, for papers by Judy Cossins Breakdown of academic impact, for papers by Yonghao Cao
Rankless by CCL
2026